Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 524 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Cancer Research Network Clear all

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2033
U.S. locations: 59
States / cities: Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab; Drug
Lead sponsor: Nasser Hanna, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 15
States / cities: Duarte, California • Fort Wayne, Indiana • Goshen, Indiana + 9 more

Conditions: Oropharyngeal Cancer
Interventions: Lymphatic Mapping with SPECT-CT, Ipsilateral and Contralateral Neck; Other · Radiation
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 28
States / cities: Corona, California • Duarte, California • Irvine, California + 21 more

Conditions: Lymphoma
Interventions: biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 16 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2011
U.S. locations: 191
States / cities: Anchorage, Alaska • Berkeley, California • Burlingame, California + 127 more

Conditions: Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
Interventions: genotype-directed dosing with dosing software based on therapeutic drug monitoring; Other
Lead sponsor: The University of Queensland; Other
Eligibility: 2 Years and older
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: bicalutamide, goserelin, mitoxantrone hydrochloride, prednisone; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 983 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2018
U.S. locations: 234
States / cities: Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 157 more

Conditions: Esophageal Cancer
Interventions: fluorouracil, oxaliplatin, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 143
States / cities: Mobile, Alabama • Anchorage, Alaska • Bentonville, Arkansas + 92 more

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: cytogenetic analysis, fluorescence in situ hybridization; Genetic
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 3,341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2012
U.S. locations: 280
States / cities: Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 182 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Cancer Research Network; Other
Eligibility: Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 2
States / cities: Plantation, Florida • Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Cisplatin, Rucaparib; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 27
States / cities: Fullerton, California • Los Angeles, California • Santa Maria, California + 22 more

Conditions: Breast Cancer, Brain Metastases, Adult
Interventions: Olaparib, Stereotactic Radiosurgery, Durvalumab, Physicians Choice systemic chemotherapy; Drug · Radiation
Lead sponsor: Colette Shen; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more

Conditions: Germ Cell Neoplasms, Testicular Neoplasms, Non Seminomatous Germ Cell Tumors, Mediastinal Neoplasms, Genital Neoplasms, Male, Genital Neoplasms, Female, Ovarian Neoplasms
Interventions: Pembrolizumab; Drug
Lead sponsor: Nasser Hanna, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Indianapolis, Indiana • Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: PTK787, Trastuzumab; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 8
States / cities: Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more

Conditions: Colorectal Cancer
Interventions: fluorouracil, leucovorin calcium; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2015
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Multiple Myeloma, Smoldering Myeloma, Waldenstrom's Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Amyloidosis
Interventions: biologic sample preservation procedure; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 207
States / cities: Little Rock, Arkansas • Berkeley, California • Burlingame, California + 141 more

Conditions: Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions: Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin; Drug · Other · Procedure + 1 more
Lead sponsor: ETOP IBCSG Partners Foundation; Network
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 3,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2024
U.S. locations: 480
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more

Conditions: Breast Cancer, Musculoskeletal Complications, Pain
Interventions: duloxetine hydrochloride, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 714
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more

Conditions: Prostate Cancer
Interventions: Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 16
States / cities: Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 12 more

Conditions: Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer, Limited Stage Small-Cell Lung Cancer
Interventions: Durvalumab, Monalizumab, Carboplatin or Cisplatin, Etoposide; Drug
Lead sponsor: Khalil Choucair; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 4
States / cities: Indianapolis, Indiana • Iowa City, Iowa • Detroit, Michigan + 1 more

Conditions: Colorectal Cancer
Interventions: Branch I, Branch II, Branch III, Branch IV, Branch V; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 50 Years to 74 Years
Enrollment: 7,711 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Fort Worth, Texas

Conditions: Ovarian Cancer
Interventions: Sorafenib, Topotecan; Drug
Lead sponsor: Daniela Matei, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: Galesburg, Illinois • Evansville, Indiana • Fort Wayne, Indiana + 4 more

Conditions: Breast Cancer
Interventions: Radiation, No Radiation; Radiation · Other
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 35 Years and older · Female only
Enrollment: 2,138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 451
States / cities: Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more

Conditions: Rectal Carcinoma, Rectosigmoid Carcinoma
Interventions: Best Practice, Dietary Intervention, Message, Quality-of-Life Assessment, Questionnaire Administration; Other · Dietary Supplement
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 225
States / cities: Tucson, Arizona • Costa Mesa, California • Duarte, California + 144 more

Conditions: Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Distal Bile Duct Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Gallbladder Cancer AJCC v8, Stage IVB Gallbladder Cancer AJCC v8, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 692
States / cities: Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 448 more

Search by objective public record fields.

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction

S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed

S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers